Edward A. Smith, MD, MPH, founder and CEO, is an accomplished Internal Medicine specialist, Harvard trained biostatistician and clinical trialist and cancer researcher. Dr. Smith worked with Dr. Bittner, Dr. Dougherty and Dr. Jeffrey Trent at the National Institutes of Health. Dr. Smith is an adjunct faculty member at the University of Arizona College of Medicine and TGen. Prior to this, Dr. Smith had extensive business leadership experience as CEO of the Diagnostic Clinic, an Internal Medicine clinic employing 12 physicians and over 40 support staff, CEO of WellPower, Inc., a disease management company with over 20 doctors and nurses and over 50 support staff and CMO for LifeCare Resources.
Paul Kreutz Esq., Founder, VP for Strategic Affairs and General Counsel. Mr. Kreutz has extensive experience working with biotech start-ups both in the San Francisco and San Diego areas.
Mike Bittner, PhD, Principal Investigator for the PBS-Bio technology at TGen and PBS-Bio Scientific Advisory Board member. Dr. Bittner is widely recognized as one of the most important forces in microarray analysis and functional genomics in the world having published the first microarray study in humans with Joe DeRisi. He is also inventor of much of the microarray analysis tools in use today.
Spyro Mousses, PhD, PBS-Bio Scientific Advisory Board and Head of the Cancer Drug Development Laboratory. Director, Pharmaceutical Genomics Division Translational Genomics Research Institute (TGen).
Ed Dougherty, PhD, Principal Investigator at TGen, PBS-Bio Scientific Advisory Board and and Director of the Genomics Signaling Processing Lab at Texas A&M University. He is a Rutgers trained mathematician and electrical engineer having authored over 170 publications in signal processing and computational biology. He is recognized as one of the world's pioneers and contemporary experts in the field of computer image analysis.
Andrew Allen, MD, PhD, PBS-Bio Scientific Advisory Board. Dr. Allen has a long history of working in the pharmaceutical industry having been Medical VP for Pharmion, VP and Head of the Oncology Therapeutic Unit at Novartis / Chiron.
Bahija Jallal, PhD, PBS-Bio Scientific Advisory Board. Vice President, Translational Sciences at MedImmune, and previously VP of Drug Assessment and Development and Translational Medicine Group at Novartis / Chiron.
Michael Gordon, MD, Premiere Oncology, a national oncology research group.